Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
06 mars 2024 16h09 HE
|
Zymeworks Inc.
Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of...
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
05 mars 2024 16h30 HE
|
Zymeworks Inc.
Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidatesStrong preclinical activity across...
Zymeworks Announces Participation in Upcoming Investor Conferences
27 févr. 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
14 févr. 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
08 févr. 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Participation in Upcoming Investor Conferences
31 janv. 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
04 janv. 2024 06h15 HE
|
Zymeworks Inc.
Company well-positioned for further progress and broadening of R&D pipelineCash resources of approximately $455 million as of December 31, 2023 (unaudited)Expected cash runway, including proceeds...
Zymeworks Announces Additional Leadership Appointments
04 janv. 2024 06h00 HE
|
Zymeworks Inc.
Dr. Jeffrey Smith named Executive Vice President and Chief Medical OfficerDr. John Fann promoted to Senior VP, Process SciencesSeven new Vice Presidents appointed, underscoring commitment to...
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
26 déc. 2023 08h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today...
Zymeworks Added to Nasdaq Biotechnology Index
15 déc. 2023 08h30 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...